Thrombolytic therapy vs heparin: primary outcome measures: Minor haemorrhagic events (duration of
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Thrombolytic therapy vs heparin: primary outcome measures Minor haemorrhagic events (duration of · people with acute PE Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty). Thrombolytic therapy for pulmonary embolism (2021) · Cochrane Headline outcomes only | OR 2.97 [1.66, 5.3] | 13 studies · 1757 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Thrombolytic therapy for pulmonary embolism 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.